Breed's Hill Capital’s Amgen AMGN Stock Holding History

Breed's Hill Capital’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-749	Closed	-$233K	–	142
2025 Q1	$233K	Buy	+749	New	+$221K	0.13%	115

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Breed's Hill Capital's AMGN Position: Q2 2025 in Review

Breed's Hill Capital sold out of Amgen (AMGN) in Q2 2025, closing a stake of 749 shares — an estimated $233K sold.

Breed's Hill Capital first reported a position in AMGN in Q1 2025 and held it in 1 quarter. The position peaked at $233K in Q1 2025. 2,857 funds tracked by Wall St. Rank hold AMGN as of Q2 2025.

Breed's Hill Capital reported no remaining Amgen position as of Q2 2025 after selling out during the quarter.
Breed's Hill Capital sold 749 Amgen shares in Q2 2025, an estimated $233K.
Breed's Hill Capital first reported a position in Amgen in Q1 2025 and held it in 1 quarter.
Breed's Hill Capital's Amgen position peaked at $233K in Q1 2025.
2,857 funds tracked by Wall St. Rank held Amgen as of Q2 2025.

Based on Breed's Hill Capital's 13F filing for Q2 2025, filed 8 Aug 2025.